← Back to Search

Intervention for Atrial Fibrillation (IMPACT-AFib Trial)

N/A
Waitlist Available
Research Sponsored by Harvard Pilgrim Health Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up follow-up through the date on which at least 80% of eligible study participants have at least 12 months of follow-up time
Awards & highlights

IMPACT-AFib Trial Summary

This trial will test whether educating patients and providers on stroke prevention in atrial fibrillation can result in increased use of oral anticoagulants for stroke prevention.

Eligible Conditions
  • Atrial Fibrillation
  • Stroke

IMPACT-AFib Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~follow-up through the date on which at least 80% of eligible study participants have at least 12 months of follow-up time
This trial's timeline: 3 weeks for screening, Varies for treatment, and follow-up through the date on which at least 80% of eligible study participants have at least 12 months of follow-up time for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients with evidence of at least one OAC dispensing (prescription fill) (defined as one OAC dispensing or 4 INR (International Normalized Ratio) tests)
Secondary outcome measures
All-cause in-hospital mortality rates
Health care utilization for AF patients
Proportion of days covered by OAC dispensing
+8 more

IMPACT-AFib Trial Design

2Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
Group II: ControlExperimental Treatment1 Intervention
Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.

Find a Location

Who is running the clinical trial?

Harvard Pilgrim Health CareLead Sponsor
54 Previous Clinical Trials
27,716,312 Total Patients Enrolled
Clinical Trials Transformation InitiativeOTHER
1 Previous Clinical Trials
7,530 Total Patients Enrolled
Duke Clinical Research InstituteOTHER
63 Previous Clinical Trials
176,866 Total Patients Enrolled
5 Trials studying Atrial Fibrillation
31,622 Patients Enrolled for Atrial Fibrillation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation
Richard Platt 2017. "IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03259373.
~8527 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top